Novel wound-healing drug to go on sale

Published: 2004-11-26 06:56:00

Updated: 2004-11-26 06:56:00

Daewoong Pharm said it signed with a licensing contract with the U.S.-based Lescarden Inc. for the exclusive distribution of Catrix, a bovine-derived complex mucopolysaccharide product, in Korea.

The unique, demonstrated ability of Catrix to expedite the development of epithelial cells makes i...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK